Author: Gérald Mongin
Publisher: Adis International
ISSN: 1173-2563
Source: Clinical Drug Investigation, Vol.24, Iss.9, 2004-01, pp. : 545-558
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Objective: To compare the 24-hour sustained efficacy and safety of a new tramadol once-daily formulation (tramadol OAD) using Contramid® controlled-release technology with a marketed twice-daily formulation (tramadol BID).Patients, design and setting: 431 patients with osteoarthritis of the knee were enrolled in this randomised, double-blind, multicentre, parallel study. After titration to optimum dose (range 100400mg), patients received medication for 12 weeks.Main outcome measures and results: Efficacy evaluations included: Western Ontario and McMaster University Osteoarthritis Index (WOMAC) scores (pain, stiffness, physical function and global), daily efficacy ratings (post-dose: tramadol OAD 24 hours; tramadol BID 12 hours), pain ratings over 24 hours, and patient and investigator overall ratings. Non-inferiority was demonstrated for the primary endpoint, mean percentage change in WOMAC pain score from baseline to week 12 (tramadol OAD 58%; tramadol BID 59%) [95% CI -7.67, 3.82]. The median optimum dose received was 200mg (both treatments). In 73% of patients, pain was mild to absent at the end of the dosing interval for both treatments (tramadol OAD 24 hours; tramadol BID 12 hours). Pain ratings over 24 hours were similar between groups, indicating 24-hour sustained efficacy for tramadol OAD. More tramadol BID patients reported dizziness/vertigo (37% vs 26%), vomiting (14% vs 8%) and headache (18% vs 13%) while tramadol OAD patients reported more somnolence (30% vs 21%). Conclusions: This study demonstrated that this novel tramadol OAD formulation provides sustained analgesic efficacy over the entire 24-hour dosing interval and a clinically favourable safety profile, both of which will provide a clear clinical benefit.
Related content
By van Wyk Jean Qaqish Roula Hollar Kimberly White Kelly D’’Amico Ronald Norton Michael Chiu Yi-Lin King Martin
Future Virology, Vol. 7, Iss. 1, 2012-01 ,pp. :
Arthritis & Rheumatism, Vol. 62, Iss. 12, 2010-12 ,pp. :
By Pueyo C. Diaz C. Sol J. Masramon X. Hernandez G.
Clinical Drug Investigation, Vol. 20, Iss. 2, 2000-08 ,pp. :
Once-daily carmoterol challenges twice-daily formoterol in asthma
Inpharma, Vol. 1, Iss. 1562, 2006-01 ,pp. :